Phase 3 N=2,091 Study to Investigate the Efficacy of Symbicort® SMART.
Asthma
Primary: The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study — 16; 22 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=833 A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates
Postmenopausal Osteoporosis
Primary: Total Hip Bone Mineral Density Percent Change From Baseline at Month 12 — 2.2; 0.9 Percentage Change From Baseline — p=<0.0001
Phase 3 N=8,388 Hutchinson Smoking Prevention Project
Smoking Among Youth
Primary: Number of Participants Smoking Daily at 12th Grade — 995; 976 participants
Phase 3 N=242 Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
Low Bone Mass · Low Bone Mineral Density · Males With Osteoporosis
Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 — 0.9; 5.7 Percent — p=<0.0001
Phase 3 N=253 Self Selection Trial of Naproxen Sodium
Pain
Primary: The Percentage of Participants Who Selected Naproxen Sodium ER and Expected Their Pain to Last More Than 12 Hours — 72.0 Percentage of participants
Phase 3 N=75 Comparing Desflurane to Sevoflurane for the Effect on Recovery Time in Patients Undergoing Urological Cystoscope Surgery
Cystoscopes · Baxter Anaesthesia Brand of Desflurane · Sevoflurane
Primary: Recovery Time — 9; 20 Minutes
Phase 3 N=867 Immunogenicity Study of the Japanese Encephalitis Vaccine IC51
Japanese Encephalitis
Primary: SCR (Seroconversion Rate)of IC51 Compared to JE-VAX at Day 56 — 96.4; 93.6 percentage of participants
Phase 3 N=1,614 First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
Colorectal Cancer
Primary: Progression Free Survival — 9.9; 10.3 Months
Phase 3 N=140 FS VH S/D 500 S-apr in Vascular Surgery
Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses
Primary: Percentage of Participants Who Achieved Hemostasis at 4 Minutes Post Treatment Application. — 62.9; 31.4 Percentage of participants — p=<0.0001
Phase 3 N=274 A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants With Clinical Remission at 8 Weeks — 11.5; 13.8; 10.0 percentage of participants
Phase 3 N=132 Immunogenicity and Safety of Adacel Polio Vaccine
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants With Seroprotection to Vaccine Antigens Following Vaccination With ADACEL Polio (TdcP-IPV) Vaccine. — 131; 131; 131; 131 Participants
Phase 3 N=820 Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 26 — -1.53; -1.48; -1.63; -1.15 percentage of total hemoglobin — p=0.620
Phase 3 N=325 A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)
Insomnia
Primary: Incidence of Adverse Events — 81.5; 79.5; 82.1; 87.0 Percentage of Participants
Phase 3 N=177 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Retinal Vein Occlusion
Primary: Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants…
Phase 3 N=712 Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Refractory Partial Seizures
Primary: Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) — -10.69; -13.63; -23.33; -30.80…